PTCTPTC Therapeutics, Inc.

PTCT Stock Price, Valuation & Chart | PTC Therapeutics, Inc.

Compare

$70.560+1.02 (+1.47%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology PTCT intrinsic value PTCT calculated fair value vs price

Overview Financials Dividends Ratios

PTCT Historical price chart

PTCT Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization5.89B

PE Ratio-30.28

EPS-2.33

Trading Volume691.01K

Today's High/Low70.69/69.05

Dividend Yield0.00

52 Week High/Low90.87/49.38

Shares Outstanding83.46M

PTCT Financial Statement

PTCT Analyst ratings

PTCT Analysis & performance metrics

PTCT Company profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio…

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for…

PTCT Management team

Name

Position

Pierre Gravier M.S.CFO

Chief Financial Officer

Lee Golden M.D., Ph.D.

Executive Vice President & Chief Medical Officer

Mark Elliott Boulding J.D.

Executive Vice President & Chief Legal Officer

Jane Baj

Vice President of Corporate Communications

Allan Steven Jacobson Ph.D.CTO

Co-Founder & Independent Director

Matthew B. Klein F.A.C.S., M.D., M.S.CEO

Chief Executive Officer & Director

Christine Utter CPA

Senior Vice President, Chief Accounting Officer & Head of People Services

Linda Montella CarterCTO

Senior Vice President & Chief Information Officer

Name

Position

Pierre Gravier M.S.CFO

Chief Financial Officer

Lee Golden M.D., Ph.D.

Executive Vice President & Chief Medical Officer

Mark Elliott Boulding J.D.

Executive Vice President & Chief Legal Officer

Jane Baj

Vice President of Corporate Communications

Allan Steven Jacobson Ph.D.CTO

Co-Founder & Independent Director

Matthew B. Klein F.A.C.S., M.D., M.S.CEO

Chief Executive Officer & Director

Christine Utter CPA

Senior Vice President, Chief Accounting Officer & Head of People Services

Linda Montella CarterCTO

Senior Vice President & Chief Information Officer

Management Team

Pierre Gravier M.S.CFO

Chief Financial Officer

Lee Golden M.D., Ph.D.

Executive Vice President & Chief Medical Officer

Mark Elliott Boulding J.D.

Executive Vice President & Chief Legal Officer

Jane Baj

Vice President of Corporate Communications

Allan Steven Jacobson Ph.D.CTO

Co-Founder & Independent Director

Matthew B. Klein F.A.C.S., M.D., M.S.CEO

Chief Executive Officer & Director

Christine Utter CPA

Senior Vice President, Chief Accounting Officer & Head of People Services

Linda Montella CarterCTO

Senior Vice President & Chief Information Officer

Management

Pierre Gravier M.S.CFO

Chief Financial Officer

Lee Golden M.D., Ph.D.

Executive Vice President & Chief Medical Officer

Mark Elliott Boulding J.D.

Executive Vice President & Chief Legal Officer

Jane Baj

Vice President of Corporate Communications

Allan Steven Jacobson Ph.D.CTO

Co-Founder & Independent Director

Matthew B. Klein F.A.C.S., M.D., M.S.CEO

Chief Executive Officer & Director

Christine Utter CPA

Senior Vice President, Chief Accounting Officer & Head of People Services

Linda Montella CarterCTO

Senior Vice President & Chief Information Officer

Total 8 executives

PTCT Frequently asked questions

What is PTC Therapeutics, Inc. (PTCT) Stock Price?

Current stock price of PTC Therapeutics, Inc. (PTCT) stock is $70.560. The stock price is +1.47% higher in the session. The intraday range can be seen from this page. Volume of PTC Therapeutics, Inc. (PTCT) stock is 691.01K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the PTC Therapeutics, Inc. (PTCT) stock price going up or down today?

The stock price of PTC Therapeutics, Inc. (PTCT) can change with earnings, company news, and overall market sentiment. PTC Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the PTC Therapeutics, Inc. stock expensive at its current price?

Whether PTC Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PTCT on this page is -30.28. EPS on this page is -2.33. Compare those figures with peers and growth expectations before deciding if the current PTC Therapeutics, Inc. price is justified.

How has the stock price of PTC Therapeutics, Inc. (PTCT) performed historically?

Historical performance for PTC Therapeutics, Inc. (PTCT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PTCT reacted to past earnings and market events.

Should I buy PTC Therapeutics, Inc. (PTCT) stock, at this price?

Buying PTC Therapeutics, Inc. (PTCT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.